Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Food Scene
Community Directory
Community Service
Restaurant Guide
Rescue Me
Other
Specials
Entertainment Now
Spring Wellness
Home & Garden
Home Improvement
Home & Realty
Horizons
Outdoor Guide
Progress
Women
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2022 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomea Fusion Inc
(NQ:
BMEA
)
15.05
-0.18 (-1.18%)
Streaming Delayed Price
Updated: 3:15 PM EDT, Mar 22, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
305,549
Open
15.00
Bid (Size)
15.02 (2)
Ask (Size)
15.15 (4)
Prev. Close
15.23
Today's Range
14.69 - 16.01
52wk Range
2.840 - 16.74
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
March 14, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival...
Via
FinancialNewsMedia
Exposures
Product Safety
Biomea Fusion To Participate In Upcoming Investor Events
March 02, 2023
From
Biomea Fusion, Inc.
Via
Globe NewsWire
Performance
YTD
+77.48%
+77.48%
1 Month
+38.71%
+38.71%
3 Month
+74.80%
+74.80%
6 Month
+32.95%
+32.95%
1 Year
+172.64%
+172.64%
More News
Read More
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
February 24, 2023
Via
Benzinga
Why Shares of Biomea Fusion Jumped This Week
January 20, 2023
Via
The Motley Fool
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors
January 17, 2023
From
Biomea Fusion, Inc.
Via
Globe NewsWire
Analyst Expectations for Biomea Fusion's Future
January 13, 2023
Via
Benzinga
US Stocks Edge Lower; Bank of America Profit Tops Views
January 13, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 13, 2023
Via
Benzinga
Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
January 09, 2023
From
Biomea Fusion, Inc.
Via
Globe NewsWire
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219
January 04, 2023
From
Biomea Fusion, Inc.
Via
Globe NewsWire
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes
December 14, 2022
From
Biomea Fusion, Inc.
Via
Globe NewsWire
Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date
December 12, 2022
From
Biomea Fusion, Inc.
Via
Globe NewsWire
Is Ardelyx is A Buy After Slip in Early 2022
November 21, 2022
Via
MarketBeat
Exposures
Product Safety
Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference
November 11, 2022
From
Biomea Fusion, Inc.
Via
Globe NewsWire
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights
November 07, 2022
From
Biomea Fusion, Inc.
Via
Globe NewsWire
Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting
November 03, 2022
From
Biomea Fusion, Inc.
Via
Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Via
Benzinga
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219
October 31, 2022
From
Biomea Fusion, Inc.
Via
Globe NewsWire
Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial
October 27, 2022
From
Biomea Fusion, Inc.
Via
Globe NewsWire
BMF-219 Enters the Clinic for KRAS Solid Tumors
October 14, 2022
From
Biomea Fusion, Inc.
Via
Globe NewsWire
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
August 26, 2022
Via
Benzinga
Biomea Fusion Touts Additional Preclinical Data For Blood Cancer Candidate
August 26, 2022
Via
Benzinga
How Is The Market Feeling About Biomea Fusion?
August 18, 2022
Via
Benzinga
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
August 18, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 17, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
